Parkinson's disease and parkinsonism: Neuropathology

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 8, 2012, Pages

  Dickson, Dennis W ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; TAR DNA BINDING PROTEIN; TAU PROTEIN;

ARTICLE; BODY POSTURE; BRAIN ATROPHY; CELL INCLUSION; CEREBELLAR PEDUNCLE; CORTICOBASAL DEGENERATION; DIFFUSE LEWY BODY DISEASE; DYSARTHRIA; FALLING; HUMAN; LEWY BODY; NERVE DEGENERATION; NEURITE; PARKINSON DISEASE; PARKINSONISM; PONTINE NUCLEUS; PROGRESSIVE SUPRANUCLEAR PALSY; SHY DRAGER SYNDROME; STAGING; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; SUPERIOR CEREBELLAR PEDUNCLE; TAUOPATHY; TDP 43 PROTEINOPATHY; TRAUMATIC BRAIN INJURY;

PARKINSONIA;

EID: 84872729641     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a009258     Document Type: Article

References (87)

1. Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, GrandinettiA, Blanchette PL, Popper JS, Ross GW. 2001. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 57: 456-462.
2. Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, Sasse J, BoyerS, Shirohi S, Brooks R, et al. 2009. Unified staging system for Lewy body disorders: Correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 117: 613-634.
3. Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White Iii CL, Akiyama H, Caviness JN, Shill HA, Sabbagh MN, et al. 2010. Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 119: 689-702.
4. Berendse HW, Booij J, Francot CM, Bergmans PL, Hijman R, Stoof JC, WoltersEC. 2001. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann Neurol 50: 34-41.
5. Boeve BF, Maraganore DM, Parisi JE, Ahlskog JE, Graff-Radford N, Caselli RJ, Dickson DW, Kokmen E, Petersen RC. 1999. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 53: 795-800.
6. Braak H, Del Tredici K. 2009. Neuroanatomy and pathology of sporadic Parkinson's disease. Adv Anat Embryol Cell Biol 201: 1-119.
7. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. 2004. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318: 121-134.
8. Buee-Scherrer V, Buee L, Hof PR, Leveugle B, Gilles C, Loerzel AJ, Perl DP, Delacourte A. 1995. Neurofibrillary degeneration in amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam. Immunochemical characterization of tau proteins. Am J Pathol 146: 924-932.
9. Buratti E, Baralle FE. 2010. The multiple roles of TDP-43 in pre-mRNA processing and gene expression regulation. RNA Biol 7: 420-429.
10. Conway KA, Harper JD, Lansbury PT Jr. 2000. Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39: 2552-2563.
11. Crowther RA, Daniel SE, Goedert M. 2000. Characterisation of isolated α-synuclein filaments from substantia nigra of Parkinson's disease brain. Neurosci Lett 292: 128-130.
12. Dale GE, Probst A, Luthert P, Martin J, Anderton BH, Leigh PN. 1992. Relationships between Lewy bodies and pale bodies in Parkinson's disease. Acta Neuropathol (Berl) 83: 525-529.
13. Del Tredici K, Rub U, De Vos RA, Bohl JR, Braak H. 2002. Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 61: 413-426.
14. de Silva R, Lashley T, Gibb G, Hanger D, Hope A, Reid A, Bandopadhyay R, Utton M, Strand C, Jowett T, et al. 2003. Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol Appl Neurobiol 29: 288-302.
15. Dickson DW. 1999. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J Neurol 246: 116-115.
16. Dickson DW. 2001. α-Synuclein and the Lewy body disorders. Curr Opin Neurol 14: 423-432.
17. Dickson DW. 2004. Sporadic tauopathies: Pick's disease, corticobasal degeneration, progressive supranuclear palsy and argyrophilic grain disesase. InThe neuropathology of dementia, 2nd ed. (ed. MM Esiri, VMY Lee, JQTrojanowski), pp. 227-256. Cambridge University Press, New York.
18. Dickson DW, Bergeron C, Chin SS, Duyckaerts C, Horoupian D, Ikeda K, Jellinger K, Lantos PL, Lippa CF, Mirra SS, et al. 2002. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 61: 935-946.
19. Dickson DW, Rademakers R, Hutton ML. 2007. Progressive supranuclear palsy: Pathology and genetics. Brain Pathol 17: 74-82.
20. Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J, Leverenz JB, Del Tredici K, Wszolek ZK, et al. 2009. Neuropathological assessment of Parkinson's disease: Refining the diagnostic criteria. Lancet Neurol 8: 1150-1157.
21. Dickson DW, Ahmed Z, Algom AA, Tsuboi Y, Josephs KA. 2010. Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol 23: 394-400.
22. Evidente VG, Adler CH, Sabbagh MN, Connor DJ, Hentz JG, Caviness JN, Sue LI, Beach TG. 2011. Neuropathological findings of PSP in the elderly without clinical PSP: Possible incidental PSP? Parkinsonism Relat Disord 17: 365-371.
23. Farrer MJ. 2006. Genetics of Parkinson disease: Paradigm shifts and future prospects. Nat Rev Genet 7: 306-318.
24. Feany MB, Dickson DW. 1995. Widespread cytoskeletal pathology characterizes corticobasal degeneration. Am J Pathol 146: 1388-1396.
25. Forno LS. 1969. Concentric hyalin intraneuronal inclusions of Lewy type in the brains of elderly persons (50 incidental cases): Relationship to parkinsonism. J Am Geriatr Soc 17: 557-575.
26. Frigerio R, Fujishiro H, Ahn TB, Josephs KA, Maraganore DM, DelleDonne A, Parisi JE, Klos KJ, Boeve BF, Dickson DW, et al. 2011. Incidental Lewy body disease: Do some cases represent a preclinical stage of dementia with Lewy bodies? Neurobiol Aging 32: 857-863.
27. Fujishiro H, Tsuboi Y, Lin WL, Uchikado H, Dickson DW. 2008a. Co-localization of tau and α-synuclein in the olfactory bulb in Alzheimer's disease with amygdala Lewy bodies. Acta Neuropathol 116: 17-24.
28. Fujishiro H, Ahn TB, Frigerio R, DelleDonne A, Josephs KA, Parisi JE, Eric Ahlskog J, Dickson DW. 2008b. Glial cytoplasmic inclusions in neurologically normal elderly: Prodromal multiple system atrophy? Acta Neuropathol 116: 269-275.
29. Galloway PG, Mulvihill P, Perry G. 1992. Filaments of Lewy bodies contain insoluble cytoskeletal elements. Am J Pathol 140: 809-822.
30. Galvin JE, Lee VM, Baba M, Mann DM, Dickson DW, Yamaguchi H, Schmidt ML, Iwatsubo T, Trojanowski JQ. 1997. Monoclonal antibodies to purified cortical Lewy bodies recognize the mid-size neurofilament subunit. Ann Neurol 42: 595-603.
31. Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, KaufmannH, Klockgether T, Lang AE, Lantos PL, et al. 1999. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 163: 94-98.
32. Halliday GM, Holton JL, Revesz T, Dickson DW. 2011. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 122: 187-204.
33. Hauw JJ, Verny M, Delaere P, Cervera P, He Y, Duyckaerts C. 1990. Constant neurofibrillary changes in the neocortex in progressive supranuclear palsy. Basic differences with Alzheimer's disease and aging. Neurosci Lett 119: 182-186.
34. Hawkes CH, Shephard BC, Daniel SE. 1997. Olfactory dysfunction in Parkinson's disease. J Neurol Neurosurg Psychiatry 62: 436-446.
35. Hawkes CH, Del Tredici K, Braak H. 2009. Parkinson's disease: The dual hit theory revisited. Ann NY Acad Sci 1170: 615-622.
36. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. 2008. The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years. Mov Disord 23: 837-844.
37. Hirano A, Kurland LT, Krooth RS, Lessell S. 1961. Parkinsonism-dementia complex, an endemic disease on the island of Guam. I. Clinical features. Brain 84: 642-661.
38. Hoglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, et al. 2011. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 43: 699-705.
39. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. 2002. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125: 861-870.
40. Ikeda K, Ikeda S, Yoshimura T, Kato H, Namba M. 1978. Idiopathic Parkinsonism with Lewy-type inclusions in cerebral cortex. A case report. Acta Neuropathol (Berl) 41: 165-168.
41. Irizarry MC, Growdon W, Gomez-Isla T, Newell K, George JM, Clayton DF, Hyman BT. 1998. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain α-synuclein immunoreactivity. J Neuropathol Exp Neurol 57: 334-337.
42. Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW. 2003. Colocalization of tau and α-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 62: 389-397.
43. Jain S. 2011. Multi-organ autonomic dysfunction in Parkinson disease. Parkinsonism Relat Disord 17: 77-83.
44. Jellinger KA. 1991. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 14: 153-197.
45. Josephs KA, Dickson DW. 2003. Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank. Mov Disord 18: 1018-1026.
46. Josephs KA, Ahmed Z, Katsuse O, Parisi JF, Boeve BF, Knopman DS, PetersenRC, Davies P, Duara R, Graff-Radford NR, et al. 2007. Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. J Neuropathol Exp Neurol 66: 142-151.
47. Kayama Y, Koyama Y. 2003. Control of sleep and wakefulness by brainstem monoaminergic and cholinergic neurons. Acta Neurochir 87: 3-6.
48. Komori T. 1999. Tau-positive glial inclusions in progressive supranuclear palsy, corticobasal degeneration and Pick's disease. Brain Pathol 9: 663-679.
49. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. 2008. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 14: 504-506.
50. Kordower JH, Dodiya HB, Kordower AM, Terpstra B, Paumier K, Madhavan L, Sortwell C, Steece-Collier K, Collier TJ. 2011. Transfer of host-derived α synuclein to grafted dopaminergic neurons in rat. Neurobiol Dis 43: 552-557.
51. Kramer ML, Schulz-Schaeffer WJ. 2007. Presynaptic α-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 27: 1405-1410.
52. Kuusisto E, Parkkinen L, Alafuzoff I. 2003. Morphogenesis of Lewy bodies: Dissimilar incorporation of α-synuclein, ubiquitin, and 62. J Neuropathol Exp Neurol 62: 1241-1253.
53. Kuzuhara S, Kokubo Y. 2005. Atypical parkinsonism of Japan: Amyotrophic lateral sclerosis-parkinsonism-dementia complex of the Kii peninsula of Japan (Muro disease): An update. Mov Disord 20: S108-S113.
54. Kuzuhara S, Mori H, Izumiyama N, Yoshimura M, Ihara Y. 1988. Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. Acta Neuropathol (Berl) 75: 345-353.
55. Lang AE. 2007. The progression of Parkinson disease: A hypothesis. Neurology 68: 948-952.
56. Langston JW. 2006. The Parkinson's complex: Parkinsonism is just the tip of the iceberg. Ann Neurol 59: 591-596.
57. Lantos PL. 1998. The definition of multiple system atrophy: A review of recent developments. J Neuropathol Exp Neurol 57: 1099-1111.
58. Lin WL, DeLucia MW, Dickson DW. 2004. α-Synuclein immunoreactivity in neuronal nuclear inclusions and neurites in multiple system atrophy. Neurosci Lett 354: 99-102.
59. Litvan I. 1999. Recent advances in atypical parkinsonian disorders. Curr Opin Neurol 12: 441-446.
60. Litvan I, Agid Y, Goetz C, Jankovic J, Wenning GK, Brandel JP, Lai EC, Verny M, Ray-Chaudhuri K, McKee A, et al. 1997. Accuracy of the clinical diagnosis of corticobasal degeneration: A clinicopathologic study. Neurology 48: 119-125.
61. Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, Kovacs GG, Ghetti B, Halliday G, Holm IE, et al. 2010. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: An update. Acta Neuropathol 119: 1-4.
62. McGeer PL, Itagaki S, Boyes BE, McGeer EG. 1988. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38: 1285-1291.
63. McKee AC, Cantu RC, Nowinski CJ, Hedley-Whyte ET, Gavett BE, Budson AE, Santini VE, Lee HS, Kubilus CA, Stern RA. 2009. Chronic traumatic encephalopathy in athletes: Progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol 68: 709-735.
64. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, DicksonD, Dubois B, Duda JE, Feldman H, et al. 2004. Dementia with Lewy bodies. Lancet Neurol 3: 19-28.
65. Morris HR, Lees AJ, Wood NW. 1999. Neurofibrillary tangle parkinsonian disorders-tau pathology and tau genetics. Mov Disord 14: 731-736.
66. Muntane G, Dalfo E, Martinez A, Ferrer I. 2008. Phosphorylation of tau and α-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related α-synucleinopathies. Neuroscience 152: 913-923.
67. Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM, Saad M, Simon-Sanchez J, Schulte C, Lesage S, et al. 2011. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: A meta-analysis of genome-wide association studies. Lancet 377: 641-649.
68. Oppenheimer DR. 1976. Diseases of the basal ganglia, cerebellum and motor neurons. In Greenfield's neuropathology, 3rd ed. (ed. Blackwood W, CorsellisJAN), pp. 608-651, Edward Arnold, London.
69. Ozawa T, Paviour D, Quinn NP, Josephs KA, Sangha H, Kilford L, Healy DG, Wood NW, Lees AJ, Holton JL, et al. 2004. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: Clinicopathological correlations. Brain 127: 2657-2671.
70. Ozawa T, Tada M, Kakita A, Onodera O, Ishihara T, Morita T, Shimohata T, Wakabayashi K, Takahashi H, Nishizawa M. 2010. The phenotype spectrum of Japanese multiple system atrophy. J Neurol Neurosurg Psychiatry 81: 1253-1255.
71. Pappolla MA, Shank DL, Alzofon J, Dudley AW. 1988. Colloid (hyaline) inclusion bodies in the central nervous system: Their presence in the substantia nigra is diagnostic of Parkinson's disease. Hum Pathol 19: 27-31.
72. Parkkinen L, Soininen H, Laakso M, Alafuzoff I. 2001. α-synuclein pathology is highly dependent on the case selection. Neuropathol Appl Neurobiol 27: 314-325.
73. Parkkinen L, Pirttila T, Tervahauta M, Alafuzoff I. 2005. Widespread and abundant α-synuclein pathology in a neurologically unimpaired subject. Neuropathology 25: 304-314.
74. Pollanen MS, Dickson DW, Bergeron C. 1993. Pathology and biology of the Lewy body. J Neuropathol Exp Neurol 52: 183-191.
75. Rajput AH, Rozdilsky B, Rajput A. 1991. Accuracy of clinical diagnosis in parkinsonism-a prospective study. Can J Neurol Sci 18: 275-278.
76. Rinne JO, Rummukainen J, Paljarvi L, Rinne UK. 1989. Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 26: 47-50.
77. Schenck CH, Bundlie SR, Mahowald MW. 1996. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 46: 388-393.
78. Schulz-Schaeffer WJ. 2010. The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol 120: 131-143.
79. Steele JC. 2005. Parkinsonism-dementia complex of Guam. Mov Disord 20: S99-S107.
80. Steele JC, Richardson JC, Olszewski J. 1964. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 10: 333-359.
81. Steele JC, Caparros-Lefebvre D, Lees AJ, Sacks OW. 2002. Progressive supranuclear palsy and its relation to pacific foci of the parkinsonism-dementia complex and Guadeloupean parkinsonism. Parkinsonism Relat Disord 9: 39-54.
82. Tiller-Borcich JK, Forno LS. 1988. Parkinson's disease and dementia with neuronal inclusions in the cerebral cortex: Lewy bodies or Pick bodies. J Neuropathol Exp Neurol 47: 526-535.
83. Uchikado H, Lin WL, DeLucia MW, Dickson DW. 2006. Alzheimer disease with amygdala Lewy bodies: A distinct form of α-synucleinopathy. J Neuropathol Exp Neurol 65: 685-697.
84. Wakabayashi K, Takahashi H. 1996. Gallyas-positive, tau-negative glial inclusions in Parkinson's disease midbrain. Neurosci Lett 217: 133-136.
85. Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Takahashi H. 2000. NACP/α-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. Acta Neuropathol (Berl) 99: 14-20.
86. Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L, Holton JL, Revesz T, Lees AJ. 2005. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 128: 1247-1258.
87. Zijlmans JC, Daniel SE, Hughes AJ, Revesz T, Lees AJ. 2004. Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord 19: 630-640.